In this formative study, 15 participants who are representative of the intended user population based on previous P-IND FDA meeting feedback, were evaluated on their ability to use the CounterAct ...
Study paves the way toward a first-ever innovation program to include AI-optimization for FDA-guided Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Petros Pharmaceuticals, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback